• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

ADAC reports 19% sales jump in Q4

Article

ADAC Laboratories posted a 19% increase in revenues for its fourthquarter (end-October), the Milpitas, CA, company reported lastweek. Operating income was also higher, although net income wasaffected due to accounting changes related to the company's

ADAC Laboratories posted a 19% increase in revenues for its fourthquarter (end-October), the Milpitas, CA, company reported lastweek. Operating income was also higher, although net income wasaffected due to accounting changes related to the company's changein income-tax status.

ADAC's fourth-quarter revenues for the most recent period were$50.2 million, compared to $42.4 million in the same period of1994. Operating income increased 45% to $5.1 million, althoughyear-to-year net income comparisons are difficult because thevendor's net income in 1994 was impacted by one-time charges relatedto litigation with Elscint and credits due to an income tax benefit.

ADAC had net income of $2.8 million in the most recent quarter,compared to net income of $6.4 million in the same period lastyear. If last year's charges and credits were excluded and thevendor had been taxed in that quarter at this year's rate of 35%,ADAC would have had net income in 1994's fourth quarter of $2.2million. ADAC's tax rate changed from the low 20% range in 1994to 35% this year due to the expiration of tax credits relatedto losses the company experienced in the 1980s.

For the year, ADAC reported revenues of $184.8 million, up 5%compared to $176.3 million in sales in 1994. Net income for 1995was $11.1 million, compared to last year's net income of $17.5million. ADAC would have recorded net income for 1994 of $12.9million if tax credits and nonrecurring charges were excluded.

As previously reported, ADAC experienced a 33% gain in bookingsfor the quarter, to a company-record $64 million.

Recent Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Detecting PCa Recurrence in African Americans: Can 18F-Flotufolastat Have an Impact?
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Related Content
© 2024 MJH Life Sciences

All rights reserved.